| Name | Title | Contact Details |
|---|
GHX is a software-as-a-service company that`s reducing the cost of doing business in healthcare by automating supply chain processes and improving visibility into the products used in patient care. We`ve built the GHX Global Network, the world`s largest community of healthcare trading partners, connecting supply chain, finance and clinical professionals with their suppliers. Our cloud-based technology makes it easier for customers to drive costs out of the healthcare supply chain. Since 2010, we`ve saved the healthcare industry $5+ billion. Today we`re expanding our solutions to further enhance data management and allow integration of clinical and business systems. The Industry We Serve Our focus is on the healthcare supply chain, through which hospitals and their suppliers buy and deliver the thousands of medical-surgical supplies that clinicians need to effectively care for patients. For most hospitals, supply chain costs are the second largest and fastest growing operational expense, so reining in these costs is imperative. Our Products and Services At the heart of GHX is the GHX Exchange, a platform that connects healthcare providers and suppliers so they can work together electronically. This helps lower costs and simplifies supply chain management by eliminating error-prone, manual order processes. GHX solutions include: • An open and neutral electronic trading exchange • Procurement and accounts payable automation • Content, contract and inventory management • Business intelligence and reporting • Standards enablement and data synchronization
Wesbury United Methodist is a Meadville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OHCOW is a Windsor, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
Excellance Inc is a Madison, AL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.